Inactive Instrument

News Discovery Laboratories, Inc. Nasdaq

Equities

US2546684034

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 16	Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 11	North American Morning Briefing : Stock Futures -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Windtree Therapeutics Announces Reverse Stock Split	Apr. 18	AQ
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates	Apr. 17	AQ
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
North American Morning Briefing : Stock Futures -2-	Apr. 11	DJ
Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call	Apr. 10
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals	Apr. 09	MT
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing	Apr. 08	AQ
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding	Apr. 07	CI
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.	Apr. 07	CI
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding	Apr. 01	CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer	Feb. 16	CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer	Feb. 16	CI
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	Feb. 01	AQ
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	Feb. 01	CI
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives	Jan. 31	CI
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives	Jan. 31	AQ
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company	Jan. 25	AQ
WINDTREE THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH LEE'S PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE ISTAROXIME, DUAL MECHANISM SERCA2A ACTIVATORS AND ROSTAFUROXIN FOR GREATER CHINA, ASIA PACIFIC REGION	Jan. 18	AQ
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region	Jan. 17	AQ
Windtree Therapeutics, Inc. Enters into License, Development and Commercialization Agreement with Lee?s Pharmaceutical (HK) Ltd	Jan. 17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Discovery Laboratories, Inc. Nasdaq

Equities

US2546684034

Summary

Filters